CalciMedica Inc. (CALC)
(Delayed Data from NSDQ)
$5.45 USD
+0.02 (0.37%)
Updated May 17, 2024 04:00 PM ET
After-Market: $5.64 +0.19 (3.49%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CALC 5.45 +0.02(0.37%)
Will CALC be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CALC based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for CALC
CalciMedica GAAP EPS of $0.01
Optimistic Buy Rating for CalciMedica Backed by Strong Financials and Promising Clinical Trials
CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
CalciMedica reports Q1 EPS 1c with items, consensus (67c)
CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024